Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid

European Journal of Clinical Pharmacology

Volumn 59, Issue 4, 2003, Pages 283-289

  Fager, Gunnar ^a   Cullberg, Marie ^a   Eriksson Lepkowska, Maria ^a   Frison, Lars ^a   Eriksson, Ulf G ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Acetylsalicylic acid; Drug drug interaction; Melagatran

Indexed keywords

ACETYLSALICYLIC ACID; MELAGATRAN; THROMBIN INHIBITOR; XIMELAGATRAN;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; EPISTAXIS; FEVER; HEADACHE; HUMAN; MALE; NORMAL HUMAN; NOSE ULCER; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ASPIRIN; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; GLYCINE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION INHIBITORS; PRODRUGS; THROMBIN; WHOLE BLOOD COAGULATION TIME;

EID: 0042913361     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0619-x     Document Type: Article

References (35)

1. Anderson FA, Wheeler HB, Goldberg RJ et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism, The Worcester DVT study. Arch Intern Med 151:933-938
2. Nordström M, Lindblad B, Bergqvist D, Kjellström T (1992) A prospective study of the incidence of deep-vein thrombosis with a defined urban population. J Intern Med 232:155-160
3. Rosendaal FR (1997) Thrombosis in the young: epidemiology and risk factors, a focus on venous thrombosis. Thromb Haemost 78:1-6
4. Becker RC, Bovill EG, Seghatchian MJ, Samama MM (1998) Pathobiology of thrombin in acute coronary syndromes. Am Heart J 136:S19-S311
5. Hirsh J (1991) Heparin. N Engl J Med 324:1565-1574
6. Hirsh J (1991) Oral anticoagulant drugs. N Engl J Med 324:1865-1875
7. Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330:1287-1294
8. Elg M, Gustafsson D, Deinum J (1997) The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 78:1286-1292
9. Elg M, Gustafsson D, Carlsson S (1999) Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 94:187-197
10. Eriksson BI, Carlsson S, Halvarsson M, Risberg B, Mattsson C (1997) Antithrombotic effect of two low molecular weight thrombin inhibitors and a low molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 78:1404-1407
11. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sörensen H (1998) Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 79:110-118
12. Gustafsson D, Nyström J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E et al (2001) The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101:171-181
13. Mattsson C, Björkman J-A, Ulvinge J-C (1997) Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinolysis Proteolysis 11:121-128
14. Mehta JL, Chen L, Nichols WW, Mattsson C, Gustafsson D, Saldeen TGP (1998) Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 31:345-351
15. Sarich TC, Eriksson UG, Mattsson C, Wolzt M, Frison L, Fager G, Gustafsson D (2002) Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 87:300-305
16. Carlsson S, Nilsson A, Börjesson I, Halvarsson M, Eriksson B, Mattsson C, Gustafsson D (1997) Melagatran, a novel low molecular weight thrombin inhibitor examined in several deep venous thrombosis models in the rat (abstract). Thromb Haemost 77[Suppl]:497
17. Bredberg U, Eriksson UG, Taure K, Johansson L, Frison L, Gustafsson D (1999) Effects of melagatran, a novel direct thrombin inhibitor, in healthy volunteers, following intravenous, subcutaneous and oral administration. Blood 94[Suppl 1]:28a
18. Eriksson UG, Johansson L, Taure K, Frison L, Bredberg U, Gustafsson D (2000) Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral, direct thrombin inhibitor H 376/95 in healthy male subjects. Haemostasis 30[Suppl 1]:164
19. Eriksson UG, Liljenvald AC, Fager G, Thuresson A, Gabrielsson M (2000) The pharmacokinetics, metabolism and elimination of H 376/95, a novel, direct thrombin inhibitor, in healthy male subjects, after oral and intravenous administration. Pharmacotherapy 20:1264
20. Eriksson BI, Arfwidsson A-C, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D (2002) A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip and knee replacement. METHRO I. Thromb Haemost 87:231-237
21. Eriksson BI, Ögren M, Eriksson UG, Kälebo P, Ahnfelt L, Björkström S, Sjöstedt Å, Folestad A, Arfwidsson A-C, Sareyko Elvander C, Frison L (2002) Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement. Results from phase II studies. Thromb Res 105:1-8
22. Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hägg A, Jonsson T, Lapidus L, Leijd B, Stockelberg D, Säfwenberg U, Taghavi A, Thorsén M (1999) Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 81:358-363
23. Eriksson H, Wåhlander K, Gustafsson D, Welin L, Frison L, Schulman S for the THRIVE I Investigators (2003) A randomised, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis. THRIVE I. J Thromb Haemost 1:41-47
24. Wåhlander K, Lapidus L, Olsson C-G, Thuresson A, Eriksson UG, Larson G, Eriksson H (2002) Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 107:93-99
25. Heir JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J et al (2002) Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Intern Med 161:2215-2221
26. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR et al (2002) Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 137:648-655
27. Lewis HD Jr, Davies JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE III, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effects of ASA against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med 309:396-403
28. Numano F, Kishi Y, Ashikaga T, Hata A, Makita T, Watanabe R (1995) What effect does controlling platelets have on atherosclerosis? Ann N Y Acad Sci 748:383-392
29. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996) European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1-13
30. Ridker PM, O'Donnell CJ, Hennekens CH (1995) Direct comparison of aspirin plus hirudin, aspirin plus heparin, and aspirin alone among 12,000 patients with acute myocardial infarction not receiving thrombolysis: rationale and design of the first American Study of Infarct Survival (ASIS-1). J Thromb Thrombolysis 1:119-124
31. Hart RG, Benavente O, Pearce LA (1999) Increased risk of intracranial hemorrhage when ASA is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 9:215-217
32. Larsson M, Logren U, Ahnoff M, Lindmark B, Abrahamsson P, Svennberg H, Persson B-A (2002) Determination of melagatran, a novel direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B 766:47-55
33. Chan TY (1995) Adverse reactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother 29:1274-1283
34. Needs CJ, Brooks PM (1985) Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 10:164-177
35. Ghahramani P, Rowland-Yeo K, Yeo WW, Jackson PR, Ramsay LE (1998) Protein binding of aspirin and salicylate measured by in vivo ultrafiltration. Clin Pharmacol Therapeut 63:285-295